We hypothesized that Durvalumab and Paclitaxel would synergistically control TNBC based on previous reports showing upregulation of PD-L1 by paclitaxel16,17 and the synergistic effect of chemotherapeutic agents and PD-L1 inhibition on promoting cancer cell apoptosis18,19. Here, CD274 is linked to cancer.